JP2025513289A5 - - Google Patents
Info
- Publication number
- JP2025513289A5 JP2025513289A5 JP2024561602A JP2024561602A JP2025513289A5 JP 2025513289 A5 JP2025513289 A5 JP 2025513289A5 JP 2024561602 A JP2024561602 A JP 2024561602A JP 2024561602 A JP2024561602 A JP 2024561602A JP 2025513289 A5 JP2025513289 A5 JP 2025513289A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- approximately
- patient
- amino acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333287P | 2022-04-21 | 2022-04-21 | |
| US63/333,287 | 2022-04-21 | ||
| US202263381752P | 2022-10-31 | 2022-10-31 | |
| US63/381,752 | 2022-10-31 | ||
| PCT/US2023/019448 WO2023205447A2 (en) | 2022-04-21 | 2023-04-21 | Uses of farnesoid x receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513289A JP2025513289A (ja) | 2025-04-24 |
| JP2025513289A5 true JP2025513289A5 (cg-RX-API-DMAC10.html) | 2026-04-28 |
Family
ID=88420596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561602A Pending JP2025513289A (ja) | 2022-04-21 | 2023-04-21 | ファルネソイドｘ受容体アゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250288600A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4511012A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025513289A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250006156A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119136794A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023257308A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3249500A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL315941A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024012966A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023205447A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097247A1 (en) * | 2022-10-31 | 2024-05-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
| US12677339B2 (en) * | 2022-11-14 | 2026-07-07 | Intel Corporation | Sensing by proxy (SBP) termination frame with termination control field |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015314830B2 (en) * | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| EA038632B1 (ru) * | 2016-03-11 | 2021-09-27 | Интерсепт Фармасьютикалз, Инк. | 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr) |
| IL271343B2 (en) * | 2017-06-23 | 2023-12-01 | Intercept Pharmaceuticals Inc | Methods and intermediates for the preparation of bile acid derivatives |
-
2023
- 2023-04-21 KR KR1020247038272A patent/KR20250006156A/ko active Pending
- 2023-04-21 CA CA3249500A patent/CA3249500A1/en active Pending
- 2023-04-21 IL IL315941A patent/IL315941A/en unknown
- 2023-04-21 AU AU2023257308A patent/AU2023257308A1/en active Pending
- 2023-04-21 US US18/858,674 patent/US20250288600A1/en active Pending
- 2023-04-21 EP EP23792602.7A patent/EP4511012A4/en active Pending
- 2023-04-21 JP JP2024561602A patent/JP2025513289A/ja active Pending
- 2023-04-21 WO PCT/US2023/019448 patent/WO2023205447A2/en not_active Ceased
- 2023-04-21 CN CN202380035124.0A patent/CN119136794A/zh active Pending
-
2024
- 2024-10-21 MX MX2024012966A patent/MX2024012966A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020186241A (ja) | 酸素化コレステロール硫酸塩（ｏｃｓ）の使用 | |
| US20070099846A1 (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide | |
| Wharton et al. | Cardiac failure in kwashiorkor | |
| JP7578243B2 (ja) | アルカリ性化剤による血液浄化 | |
| JP3721196B2 (ja) | 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用 | |
| JP2013139470A (ja) | ロイシンに富む組成物 | |
| JP2023500182A5 (cg-RX-API-DMAC10.html) | ||
| JP2023115271A5 (cg-RX-API-DMAC10.html) | ||
| IL315941A (en) | Uses of farnesoid x receptor agonists | |
| WO2022042541A1 (zh) | 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用 | |
| Sozo et al. | Effects of prenatal ethanol exposure on the lungs of postnatal lambs | |
| US6348495B1 (en) | Method for treating celiac disease | |
| CA2552529A1 (en) | Use of ribose in recovery from anaesthesia | |
| WO2012018145A2 (ja) | Ｑｏｌ改善剤 | |
| JP2002522507A (ja) | 疾患状態の処置 | |
| Lahaye et al. | Vanishing pulmonary hypertension in mixed connective tissue disease | |
| TW200940075A (en) | Agent for alleviating adverse side effects produced in interferon/ribavirin combination therapy | |
| JP2006515011A (ja) | Ｈｃｖ併用療法 | |
| JP2002114672A (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| JP3879938B2 (ja) | 抗炎症剤 | |
| JP2010208946A (ja) | 関節リウマチの予防・治療剤 | |
| JP2006515348A (ja) | 腎不全処置方法 | |
| CN110075100A (zh) | 咖啡酸苯乙酯在制备治疗/预防高尿酸相关疾病的药物/保健品方面的应用 | |
| Baird et al. | Long-duration (> 4 weeks) continuous renal replacement therapy in critical illness | |
| Chen et al. | PS-B11-7: LOSS OF C3A AND C5A RECEPTORS PROMOTES ADIPOCYTE BROWNING AND ATTENUATES DIET-INDUCED OBESITY VIA ACTIVATING INOSINE/A2AR PATHWAY |